These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19470056)

  • 1. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
    Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
    [No Abstract]   [Full Text] [Related]  

  • 2. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept for the treatment of psoriasis.
    Bissonnette R
    Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 5. Adolescent plaque psoriasis: our experience using etanercept.
    Ruiz-Villaverde R; Sánchez-Cano D; Abalos-Medina G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):976-7. PubMed ID: 19207668
    [No Abstract]   [Full Text] [Related]  

  • 6. Etanercept for psoriasis in the pediatric population: experience in nine patients.
    Hawrot AC; Metry DW; Theos AJ; Levy ML
    Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.
    Bachmeyer C; Thiolière B; Khosrotehrani K; Cattan E
    J Am Acad Dermatol; 2007 Jan; 56(1):169-70. PubMed ID: 17190640
    [No Abstract]   [Full Text] [Related]  

  • 9. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection.
    Nosotti L; Francesconi F; Izzi S; Berardesca E; Morrone A; Bonifati C
    Br J Dermatol; 2010 Jun; 162(6):1408-10. PubMed ID: 20184582
    [No Abstract]   [Full Text] [Related]  

  • 11. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy.
    Cassano N; Coviello C; Loconsole F; Miracapillo A; Vena GA
    Eur J Dermatol; 2006; 16(3):316-7. PubMed ID: 16709508
    [No Abstract]   [Full Text] [Related]  

  • 12. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
    Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
    Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy study on etanercept in patients with plaque psoriasis.
    Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
    Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
    [No Abstract]   [Full Text] [Related]  

  • 19. Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.
    Myers W; Newman M; Katz B; Gottlieb AB
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S127-8. PubMed ID: 17052536
    [No Abstract]   [Full Text] [Related]  

  • 20. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
    Safa G; Loppin M; Bousser AM; Barbarot S
    J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.